Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131567) titled 'Cetuximab combined with bevacizumab for adjuvant treatment after radical resection of biliary tract tumors: A single-arm, prospective clinical study' on Sept. 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Biliary tract malignancies (BTC)
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-21
Target Sample Size: Experimental group:32;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=341414
Published by HT Digital Cont...